Alder BioPharmaceuticals approaches rare status for a Seattle biotech


Leading up to the anticipated February 2020 FDA approval date, Alder plans to double the size of its workforce.

Previous Queen's responds to Kaiser lawsuit over 'unfair billing practices'
Next Compensation for former Partners chief executive tops $6M